Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.

Registrati

Quotazioni in diretta

KTTA Pasithea Therapeutics Corporation

1,41

0,00 (0,00%)

12 Feb 2025 - Chiuso

Dati in Delay di 15 minuti

Big Mid-Week Move From This Small Biotech

A Florida-based biotech company found quite a bit of mid-week success after it said that an external safety review committee recommended that its Phase 1 clinical trial of PAS-004...

To read the full story on AllPennyStocks.com, click here.

Grafico Azioni Pasithea Therapeutics (NASDAQ:KTTA)
Storico
Da Gen 2025 a Feb 2025

Clicca qui per i Grafici di Pasithea Therapeutics

Grafico Azioni Pasithea Therapeutics (NASDAQ:KTTA)
Storico
Da Feb 2024 a Feb 2025

Clicca qui per i Grafici di Pasithea Therapeutics

Notizie Pasithea Therapeutics Corporation - KTTA

Big Mid-Week Move From This Small Biotech
Giovedì 6 Febbraio 2025 (6 giorni fa) • AllPennyStocks.com

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Mercoledì 5 Febbraio 2025 (7 giorni fa) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
Martedì 14 Gennaio 2025 (4 settimane fa) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Mercoledì 20 Novembre 2024 (3 mesi fa) • GlobeNewswire Inc.

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Venerdì 27 Settembre 2024 (5 mesi fa) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Giovedì 26 Settembre 2024 (5 mesi fa) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
Lunedì 9 Settembre 2024 (5 mesi fa) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
Martedì 3 Settembre 2024 (5 mesi fa) • GlobeNewswire Inc.

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Mercoledì 28 Agosto 2024 (6 mesi fa) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Martedì 13 Agosto 2024 (6 mesi fa) • Edgar (US Regulatory)

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
Giovedì 13 Giugno 2024 (8 mesi fa) • GlobeNewswire Inc.

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
Martedì 28 Maggio 2024 (9 mesi fa) • GlobeNewswire Inc.

Più Pasithea Therapeutics Corporation Articoli Notizie

BNP PARIBAS ISSUANCE

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea